Position in PGEN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$3,274,020
-$262,260 QoQ
Shares Held
846,000
0.0% QoQ
Ownership
0.237%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in PGEN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026ADAGE CAPITAL PARTNERS GP, L.L.C. holds $4,595,586,445 across 121 Biotechnology names. PGEN ranks #97 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
5,475,611 | $532,503,169 | |
| 2 | RPRX |
Royalty Pharma plc
|
7,480,633 | $358,845,965 | |
| 3 | CNTA |
Centessa Pharmaceuticals plc
|
8,925,010 | $354,501,397 | |
| 4 | ROIV |
Roivant Sciences Ltd.
|
12,794,097 | $354,396,486 | |
| 5 | TNGX |
Tango Therapeutics, Inc.
|
12,809,485 | $267,974,426 | |
| 6 | PRAX |
Praxis Precision Medicines, Inc.
|
815,739 | $262,822,948 | |
| 7 | INSM |
INSMED Inc
|
900,000 | $147,168,000 | |
| 8 | AXSM |
Axsome Therapeutics, Inc.
|
737,578 | $124,665,433 |
All Filings in PGEN
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,274,020 | 846,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $3,536,280 | 846,000 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $2,783,340 | 846,000 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $16,011,920 | 11,276,000 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $16,801,240 | 11,276,000 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $12,169,253 | 10,865,405 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $10,322,134 | 10,865,405 | Shares | Sole | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||